The Novel Drug for Acid Related Diseases

Main Article Content

Rachaneeporn Chueansuwan

Abstract

          Acid suppression treatments have revolutionized the management of the acid-related disorders since the introduction of the H2-receptor antagonists (H2-RAs) and the proton pump inhibitors (PPIs). However, a number of limitations including slow onset of action, influence by cytochrome P450 polymorphisms, unsatisfactory side effects at night, and instability in acidic conditions has been noted. The major advance in the treatment of the acid-related disorders has been the development of Potassium-Competitive Acid Blockers (P-CABs), the potassium channel acid blocking drugs which block the K+,H+-ATPase K+ channel. P-CABs are food independent, reversible, have a rapid onset of action, and maintain a prolonged and consistent elevation of intragastric pH. Vonoprazan was recently innovated as a novel, orally active P-CAB. This drug does not require enteric coating as it is acid-stable, and it can be taken without food. Vonoprazan accumulates in parietal cells under both acidic and neutral conditions. It does not require an acidic environment for activation, has long-term stability at the site of action, and has satisfactory safety and tolerability. Thus, vonoprazan may address the unmet medical need for the treatment of the acid-related diseases.


          To review and summarized the published literatures to date concerning different aspects of potassium channel acid blocking P-CAB including mechanism of action, indication of treatment and long-term safety.


          Conclusion: vonoprazan is superior to conventional PPIs for suppressing acid secretion, especially at night, and there was no difference in efficacy depending on CYP2C19 genotype status. In addition, vonoprazan was shown to overcome the weaknesses associated with conventional PPIs. Thus, vonoprazan may address the unmet medical need for the treatment of acid-related diseases.

Article Details

Section
Interesting Drugs

References

Echizen H. The first-in-class potassium-competitive acid blocker, vonoprazan fumarate: pharmacokinetic and pharmacodynamic considerations. Clin Pharmacokinet 2016; 55:409-18.

Scarpignato C, Hunt RH. Editorial: towards extended acid suppression-the search continues. Aliment Pharmacol Ther 2015;42:1027-9.

Jenkins H, Sakurai Y, Nishimura A, Okamoto H, Hibberd M, Jenkins R, et al. Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects. Aliment Pharmacol Ther 2015;41:636-48.

Hunt RH, Scarpignato C. Potent acid suppression with PPIs and P-CABs: what's new?. Curr Treat Options Gastroenterol 2018;16:570-90.

Maradey-Romero C, Fass R. New and future drug development for gastroesophageal reflux disease. J Neurogastroenterol Motil 2014;20:6-16.

Oshima T, Arai E, Taki M, Kondo T, Tomita T, Fukui H, et al. Randomised clinical trial: vonoprazan versus lansoprazole for the initial relief of heartburn in patients with erosive oesophagitis. Aliment Pharmacol Ther 2019;49:140-6.

Kinoshita Y, Sakurai Y, Shiino M, Kudou K, Nishimura A, Miyagi T, et al. Evaluation of the efficacy and safety of vonoprazan in patients with nonerosive gastroesophageal reflux disease: a phase III, randomized, double-blind, placebo-controlled, multicenter study. Curr Ther Res Clin Exp 2016;81-82:1-7

Niikura R, Yamada A, Hirata Y, Hayakawa Y, Takahashi A, Shinozaki T, et al. Efficacy of vonoprazan for gastroesophageal reflux symptoms in patients with proton pump inhibitor-resistant non-erosive reflux disease. Intern Med 2018; 57:2443-50 .

Yaghoobi M, Padol S, Yuan Y, Hunt RH. Impact of oesophagitis classification in evaluating healing of erosive oesophagitis after therapy with proton pump inhibitors: a pooled analysis. Eur J Gastroenterol Hepatol 2010;22:583-90.

Ashida K, Sakurai Y, Hori T, Kudou K, Nishimura A, Hiramatsu N, et al. Randomised clinical trial: vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis. Aliment Pharmacol Ther 2016;43:240-51.

Miwa H, Uedo N, Watari J, Mori Y, Sakurai Y, Takanami Y, et al. Randomised clinical trial: efficacy and safety of vonoprazan vs. lansoprazole in patients with gastric or duodenal ulcers - results from two phase 3, non-inferiority randomised controlled trials. Aliment Pharmacol Ther 2017;45:240-52.

Tsuchiya I, Kato Y, Tanida E, Masui Y, Kato S, Nakajima A, et al. Effect of vonoprazan on the treatment of artificial gastric ulcers after endoscopic submucosal dissection: prospective randomized controlled trial. Dig Endosc 2017;29:576-83.

Yang M, He M, Zhao M, Zou B, Liu J, Luo LM, et al. Proton pump inhibitors for preventing non-steroidal anti-inflammatory drug induced gastrointestinal toxicity: a systematic review. Curr Med Res Opin 2017;3:973-80.

Mizokami Y, Oda K, Funao N, Nishimura A, Soen S, Kawai T, et al. Vonoprazan prevents ulcer recurrence during long-term NSAID therapy: randomised, lansoprazole-controlled non-inferiority and single-blind extension study. Gut 2018;67: 1042-51.

Kawai T, Oda K, Funao N, Nishimura A, Matsumoto Y, Mizokami Y, Ashida K, Sugano K. Vonoprazan prevents low-dose aspirin-associated ulcer recurrence: randomised phase 3 study. Gut 2018;67:1033-41.

Murakami K, Sakurai Y, Shiino M, Funao N, Nishimura A, Asaka M. Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study. Gut 2016;65:1439-46.

Ono S, Kato M, Nakagawa S, Mabe K, Sakamoto N. Vonoprazan improves the efficacy of Helicobacter pylori eradication therapy with a regimen consisting of clarithromycin and metronidazole in patients allergic to penicillin. Helicobacter 2017;22(3): e12374.

Malfertheiner P, Megraud F, O'Morain CA, Gisbert JP, Kuipers EJ, Axon AT, et al. Management of Helicobacter pylori infection-the Maastricht V/florence consensus report. Gut 2017;66:6-30.